Arcus Biosciences Inc. (RCUS) saw its stock price surge 5.55% during intraday trading on Monday, driven by bullish analyst sentiment.
The significant price movement follows positive actions from two investment firms. Leerink raised its price target on Arcus Biosciences to $49 from $36 while maintaining an Outperform rating on the shares. Separately, H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on the stock with a price target of $32.
These analyst updates reflect growing confidence in the company's prospects and likely contributed to the heightened investor buying activity during the trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.